Latest Headlines
-
Cytiva And Pall Life Sciences Complete Integration To Create A Global Innovation And Solutions Leader In Biotechnology
5/23/2023
Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. With nearly 16 000 associates in 40 countries, and more than 300 years’ heritage of trusted expertise, the new Cytiva supports customers in solving major biotechnology challenges and plays a critical role in advancing and accelerating therapeutics for the benefit of patients everywhere.
-
Ajinomoto Bio-Pharma Services Announces US Facility Leadership Changes
5/18/2023
Learn how leadership changes at Aji Bio-Pharma's site in San Diego will bring integral expertise to the company as it continues to expand its capacity and service offerings.
-
AGC Biologics Launches BravoAAV™ And ProntoLVV™ Platforms
5/18/2023
The new Biologics AAV and LVV platforms offer fast, efficient, and reproducible clinical and commercial GMP production and release and are supported by proprietary process and capsid-specific platform methods.
-
Synthego Opens State-Of-The-Art GMP Guide RNA Manufacturing Facility To Enable CRISPR Genomic Medicines
5/11/2023
Synthego Corp., a leading provider of genome engineering solutions, announced today the opening of its state-of-the-art GMP synthesis facility.
-
Breakthrough Properties Closes Financing And Commences Construction On New Life Sciences Development In Downtown Philadelphia
5/3/2023
Breakthrough Properties, a leading global developer of life sciences real estate backed by a joint venture of Tishman Speyer and Bellco Capital, today announced it has closed financing and commenced construction on a best-in-class life science building on Market at S. 23rd Street, in the heart of Philadelphia's vibrant Center City District.
-
New Agreement To Study Stem Cell-Derived NK Cell Expansion Technology
5/2/2023
A research agreement was recently signed to evaluate induced pluripotent stem cell-derived feeder cells to improve and accelerate the development and manufacturing of NK-based therapies.
-
Aldevron Announces Expansion Of mRNA Production Capability
5/1/2023
Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product.
-
Cryoport Expands Global Supply Chain Network Through Recent Acquisition
4/27/2023
The recent acquisition of of Cell&Co BioServices by Cryoport, Inc. will help to expand global service offerings by generating opportunities for clinical trial and cell and gene therapy developers in Europe.
-
NanoFCM Partners With RoosterBio As An Approved Service Provider For Exosome Analysis
4/26/2023
NanoFCM Co., Ltd today announced that RoosterBio, Inc., is approved to provide analytical services worldwide using NanoFCM’s NanoAnalyzer.
-
Qosina Introduces New Genderless AseptiQuik® W Series Connectors For Large-Volume, High-Flow Production Environments
4/25/2023
Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce CPC’s (Colder Products Company) new AseptiQuik® W Series connectors to its extensive line of aseptic genderless connectors.